AVX901
AXP000214.1 · Cancer vaccine
- Platform
- alphavirus (VEE) virus-like replicon particles
- Targets
- ERBB2
- Originator
- AlphaVax
- Sponsor
- Duke University
Names
Virus
- Role
- Vaccine vector
- Family
- Togaviridae
- Virus
- Venezuelan equine encephalitis virus (NCBI Taxonomy 11036)
- Strain
- VEE replicon, packaged as virus-like replicon particles
- Replication
- non replicating
- Modifications
- propagation-defective single-cycle replicon with three of seven viral genes replaced by the HER2 insert (extracellular and transmembrane domains, no intracellular domain)
- Transgenes
- ERBB2 (HER2 ECD+TM)
- Route
- intramuscular
- Source
- evidence
Cross-references
- NCI Thesaurus
- C99903
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03632941 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | Terminated | Phase 2 | 2019-03-01 | 2023-09-03 | 8 | Breast Cancer; HER2+ Breast Cancer |
| NCT01526473 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | Phase 1 | 2012-02 | 2016-03 | 22 | HER2+ Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32732224 | Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | cited by trial NCT03632941 |
| PMID 30635338 | Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in abstract: VRP-HER2 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33902424 | Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options. | Endocrine, metabolic & immune disorders drug targets | 2022 | name in abstract: AVX901 |
| PMID 29081765 | Breast Cancer Vaccines: New Insights. | Frontiers in endocrinology | 2017 | name in abstract: AVX901 |
Notes
Virus-like replicon particles encoding the HER2 extracellular and transmembrane domains (HER2 ECD+TM); single-cycle alphavirus replicon with three of seven viral genes replaced by the insert. Phase 1 in HER2-overexpressing advanced cancer (NCT01526473). The alphavirus species is not named in the trial description; VEE is taken from the shared AlphaVax VRP platform and the NCIt concept.
How to cite
AVX901 (AXP000214.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000214.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.